Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > 2-million-dollar fee
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(370)
•••
Comment by OttawaPeteron Jan 20, 2023 1:14pm
125 Views
Post# 35235939

RE:RE:RE:RE:RE:RE:RE:RE:2-million-dollar fee

RE:RE:RE:RE:RE:RE:RE:RE:2-million-dollar fee

ronrydell wrote: I agree....we could have $50 ADR's several years down the road if the glioblastoma trials worked and we got FDA approval....For us heavy share Bioasis holders...we would at least get our money back so both Medatech shareholders and Bioasis should vote yes (IMHO) and they hope and wait.

Bioasis will fold shortly staying on it's own, the requested for more debentures  to give us warrants is long gone.

 

...in several years being key phrase. It is a bunch of bs and highly unlikely given how Midatech is driving themselves into ground

bioasis will not fold if handled by a small competent management team who isn't busy working on their other company, raising for other companies. DR had total conflict of interest & total hypocrit. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities